CIGARETTES, E-CIGARETTES, AND THE ROLE OF FDA REGULATION Jennifer - - PowerPoint PPT Presentation

cigarettes e cigarettes and the role of fda regulation
SMART_READER_LITE
LIVE PREVIEW

CIGARETTES, E-CIGARETTES, AND THE ROLE OF FDA REGULATION Jennifer - - PowerPoint PPT Presentation

CIGARETTES, E-CIGARETTES, AND THE ROLE OF FDA REGULATION Jennifer Pearson, MPH, PhD Assistant Professor School of Community Health Sciences University of Nevada, Reno November 17, 2017 Top opics f s for today ys t s talk 1.


slide-1
SLIDE 1

CIGARETTES, E-CIGARETTES, AND THE ROLE OF FDA REGULATION

Jennifer Pearson, MPH, PhD Assistant Professor School of Community Health Sciences University of Nevada, Reno November 17, 2017

slide-2
SLIDE 2
  • 1. Burden of smoking
  • 2. FDA authority to regulate tobacco

products

  • 3. History and application of FDA

regulatory authority over tobacco products, applied to e-cigarettes

Top

  • pics f

s for today’ y’s t s talk

slide-3
SLIDE 3

THE BURDEN OF SMOKING

slide-4
SLIDE 4

CIGAR ARET ETTE S E SMOKIN ING I IS THE L E LEAD EADING CAUS AUSE O OF PREVE VENT NTABLE D DEATH I TH IN THE HE U USA SA

480,000/year

slide-5
SLIDE 5
slide-6
SLIDE 6

Tobacco Could Prematurely Kill 1.2 Billion Globally by 2100

By EDITH M. LEDERER. The Associated Press

Thursday, February 7, 2008; 11:52 PM

NEW YORK -- The World Health Organization warned in a new report Thursday that the "tobacco epidemic" is growing and could claim 1 billion lives by the end of the century unless governments dramatically step up efforts to curb smoking. World Health Organization Director-General Dr. Margaret Chan, right, speaks about the mpower box as New York Mayor Michael Bloomberg listens during a press conference announcing WHO's Report on the Global Tobacco Epidemic 2008 Thursday, Feb. 7, 2008 in New York. The mpower box is a symbol of the package being offered by the WHO in its effort………..

slide-7
SLIDE 7
  • 5.6 million of today’s youth

in US expected to die prematurely from smoking

  • 843.52/100,000 deaths

due to smoking in Washoe county in 2014

Smo moking i is a publi blic h health cr crisis

The burden of death and disease from tobacco use in the United States is overwhelmingly caused by cigarettes and other combusted tobacco products.

Source: U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. January 2014. The Tobacco Atlas. Country Fact Sheet: United States. Available at http://www.tobaccoatlas.org/country-data/united-states/

  • f deaths among U.S. men
  • f deaths among U.S women
slide-8
SLIDE 8
  • Drivers of smoking-related negative

health outcomes:

  • 1. Concentration of tobacco

marketing, availability, low prices in poor and minority neighborhoods

  • 2. Lack of access to smoking

cessation aids and support

  • 3. Unequal dissemination of

information about the harms

  • f smoking and benefits of

quitting

  • 4. Concentration of pro-smoking

norms, which increases initiation and decreases cessation

Smo moking i is a a soci cial j justice i issue

slide-9
SLIDE 9

“Smoki king ng i is solved”

slide-10
SLIDE 10

“Smoki king ng i is solved”

slide-11
SLIDE 11

“Smoki king ng i is solved”

slide-12
SLIDE 12
  • “The burden of death and

disease from tobacco use in the United States is

  • verwhelm

lmingly gly c caused d by cigarettes a and other combusted t d tobacc cco pr produ duct cts; rapid elimination of their use will dramatically reduce this burden.”

Smo moking c cau auses the maj majority of

  • f h

harm arm

Source: U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. January 2014. The Tobacco Atlas. Country Fact Sheet: United States. Available at http://www.tobaccoatlas.org/country-data/united-states/

slide-13
SLIDE 13
  • Smoking = combusted tobacco use, like

cigarette smoking, cigar smoking, cigarillo smoking, hookah smoking, little cigar smoking.

  • Burnt tobacco produces smoke.
  • E-cigarette use/ENDS use/vaping = using an e-

cigarette/vape pen/vape/ENDS to consume nicotine.

  • “Vaped” nicotine produces an aerosol

(commonly called “vapor”).

An An as asid ide – let’s de define ou

  • ur t

terms

slide-14
SLIDE 14

FDA AUTHORITY TO REGULATE TOBACCO PRODUCTS

slide-15
SLIDE 15

FDA regu regulat atory au auth thori rity

  • Pre

re- 2009 2009

  • Po

Post-20 2009 09

slide-16
SLIDE 16

2009 F 9 Family ly Smoki king ng P Prevent ntion a and Toba bacco cco C Control A Act

Gave FDA authority to regulate the manufacture, distribution, and marketing of tobacco products to protect public health. Created a new section of the FDA – “Center for Tobacco Products” (CTP) Initially limited to cigarettes, roll-your-own, and smokeless tobacco; expanded to all tobacco products (including e-cigarettes) in 2016.

slide-17
SLIDE 17

FDA C CTP P au authorities

  • Banned flavored cigarettes, smokeless, and

RYO tobacco (except menthol)

  • Requires cigarette & smokeless warning

labels

  • Requires disclosure of ingredients in

tobacco products

  • Required that “modified risk” claims are

supported by science

  • Banned “light,” “low,” and “mild”

descriptors

  • Allows for regulation of tobacco product

characteristics & requires premarket certification of products

slide-18
SLIDE 18

Calls for FDA CTP decision making to be based on a review of the scientific evidence regarding:

  • 1. Risks and benefits to the population as a whole,

including both users and non-users of tobacco products;

  • 2. Whether there is an increased or decreased

likelihood that existing users of tobacco products will stop using such products; and

  • 3. Whether there is an increased or decreased

likelihood that those who do not currently use tobacco products, most notably youth, will start to use tobacco products.

The Pu Publi blic H Healt lth S Stan andard

slide-19
SLIDE 19

Publ blic H Health S Stan andar ard as as a a gu guide f for

  • r re

research

Population Harm Toxicity Appeal Abuse liability

slide-20
SLIDE 20
slide-21
SLIDE 21

E-cigarette P Policy R y Rese search F Framewor

  • rk

Tob

  • bacco
  • Control

Po Policies Expo posure to P

  • Pol
  • licy

Tob

  • bacco
  • Use

e Behav avior

Health Outcomes

Psychosocial al Mediat iators Mod Moderators rs

slide-22
SLIDE 22

CASE STUDY: FDA REGULATION AND E-CIGARETTES

slide-23
SLIDE 23

So Sottera Inc. v . vs US F Food a d and d Drug A Adm dminis istration

  • 2009 – FDA denied import of

e-cigs from Smoking Everywhere and NJOY.

  • “Unapproved drug-device

combination intended to help treat withdrawal symptoms of nicotine addiction”

  • 2010 – court decided in favor
  • f companies. Found that they

are not a cessation device merely because they deliver nicotine.

  • E-cigs can be regulated as

tobacco products UNLESS they make cessation claims.

slide-24
SLIDE 24

E-cigare garettes are n not a a singl gle p product clas ass

First generation

“Cigalikes”

Second generation

“Mid-size electronic cigarettes”

Third generation

“Advanced personal vaporizers” Slide courtesy of Dr. Andrea Villanti

Fourth Generation?

Nicotine salts - JUUL

slide-25
SLIDE 25

E-cigare garettes – much l lower t r toxicity than an cigare garettes

Liquids and exhaled aerosol contain measurable amounts of:

  • Nicotine (some but not all)
  • propylene glycol (some but not all)
  • Vegetable glycerin (some but not all)
  • toxic constituents (tobacco-specific

nitrosamines, heavy metals, carbonyls), but but at much lo h lower le levels ( (9-450 t times l lowe wer) than an t tobacco smo smoke Some flavors are more cytotoxic than others, but a all a ll are re le less c cyt ytotoxic t tha han c cigarette s smoke extract

slide-26
SLIDE 26

Source: Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, Feng J, Wang L, West R. (2017). Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med. Mar 21;166(6):390-400. doi: 10.7326/M16-1107.

slide-27
SLIDE 27

E-ciga igarette e nicotine delivery – lower t than an cigar arettes?

Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Scientific Reports. 2014;4:4133.

slide-28
SLIDE 28

Ad Adults - wh who i is using e e-ciga igare rett ttes es?

Source: Schoenborn CA, Gindi RM. Electronic cigarette use among adults: United States, 2014. NCHS data brief, no. 217. Hyattsville, MD: National Center for Health Statistics. 2015.

slide-29
SLIDE 29

Ad Adult e e-cigarette u use a and cessa sation

  • n

“E-cigarette users were more likely than non-users to attempt to quit smoking, 65.1% v 40.1%, and more likely to succeed in quitting, 8.2% v 4.8%.” “The overall population cessation rate for 2014-15 was significantly higher than that for 2010-11, 5.6% v 4.5%, and higher than those for all other survey years.” “The substantial increase in e-cigarette use among US adult smokers was associated with a statistically significant increase in the smoking cessation rate at the population level.”

Source: Zhu Shu-Hong, Zhuang Yue-Lin, Wong Shiushing, Cummins Sharon E, Tedeschi Gary J. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys BMJ 2017; 358 :j3262

E-cigs rare E-cigs common

slide-30
SLIDE 30
slide-31
SLIDE 31

Mai Main c con

  • ncerns abou

about e e-cig u use an and y you

  • uth
1) 1) 1. E

E-cigarette te us use is harm e enh nhancing f for yout uth ( (and nd a all no non-tobacc cco u users).

2) While not as harmful as cigarettes, e-cigarettes are not harmless or “just water

vapor.”

3) Nicotine exposure for the adolescent brain *may* be harmful – best to avoid it. 4) 4) 2.
  • 2. E

E-cigarette te us use is a ”gateway” y” t to m more h harmful f forms tobacco us use, na namely cig igarette s smokin ing.

5) This is a difficult question to answer without an unethical RCT. 6) Data is all over the map, and conclusions depend on definitions of the

exposure and the outcome.

7) Best to think of e-cigarette use as a marker or future risk behavior (but not

necessarily causal)?

slide-32
SLIDE 32

Trends i ds in Pa Past st 30 30-Day ay Use se o

  • f Cig

Cigarettes an and d E-Cig Cigar arettes a s among H High S School S Stude dents s - NYTS TS

Source: National Youth Tobacco Survey, 2011 - 2016. 15.80% 14.00% 12.70% 9.20% 9.30% 8.00% 1.50% 2.80% 4.50% 13.40% 16.00% 11.30%

0% 2% 4% 6% 8% 10% 12% 14% 16% 18%

20 2011 11 20 2012 12 20 2013 13 20 2014 14 20 2015 15 20 2016 16 Cigarettes E-cigarettes

slide-33
SLIDE 33

Youth f frequency of pr product u use, 20 2014 N NYTS TS

Source: Villanti, A. C., et al. (2017). "Frequency of youth e- cigarette and tobacco use patterns in the U.S.: Measurement precision is critical to inform public health." Nicotine Tob Res 19(11): 1345-1350.

slide-34
SLIDE 34

It It’s ’s c com

  • mplicated!
  • How do we use policy and product regulation to

amplify any positive effects and eliminate any negative effects of e-cigarettes on public health?

  • Could ask similar questions about other consumer

products:

1.
  • 1. Alcohol
2.
  • 2. Marijuana
3.
  • 3. Prescription opioids
4.
  • 4. Automobiles
slide-35
SLIDE 35

Recent nt FDA a actions ns

slide-36
SLIDE 36

The markets react!

slide-37
SLIDE 37

Summa mmary

E-cigarettes’ ultimate effect on public health is complex and evolving. We can use policy and regulation to force companies’ priorities to align with ours (as much as possible) as public health professionals. PUBLIC HEALTH CHALLENGE: allow smokers to pursue quitting using WHA HATEVER GETS THE HEM M THE HERE RE (includin ing e-cig igar arettes), while simultaneously avoiding attracting youth e-cigarette users

slide-38
SLIDE 38

CIGAR ARET ETTE S E SMOKIN ING I IS THE L E LEAD EADING CAUS AUSE O OF PREVE VENT NTABLE D DEATH I TH IN THE HE U USA SA

480,000/year 0/year

slide-39
SLIDE 39

“The significant problems we face cannot be solved by the same level of thinking that created them.”

  • A. Einstein

Thanks for your attention! Jennifer Pearson, MPH, PhD jennipearson@unr.edu